RAD51D and breast cancer: In summary, 12.2% of high-risk breast cancer patients in our study carried non-BRCA gene mutations, with PALB2 (2.2%), ATM (1.7%), RAD51D (1.3%) and TP53 (1.3%) being the major non-BRCA genes mutated.